富马酸比索洛尔联合心舒1号治疗心力衰竭88例临床观察  

作　　者：张洪霞[1,2] 李文杰[3] 

机构地区：[1]沈阳市第七人民医院 [2]辽宁中医药大学,沈阳110003 [3]辽宁中医药大学附属第一医院

出　　处：《当代医学》2015年第5期159-160,共2页Contemporary Medicine

摘　　要：目的评价联合应用富马酸比索洛尔和心舒1号治疗心力衰竭的疗效。方法选择慢性心衰患者88例,随机均分为治疗组和对照组(n=44);对照组常规抗心衰治疗:低盐饮食,注意休息,适当进行有氧运动,应用利尿剂、地高辛、硝酸酯类药物,治疗组在上述治疗基础上加用富马酸比索洛尔和心舒1号。比较2组总体疗效。治疗前和治疗后4个月分别做超声心动图,比较2组LVEDD、LVEF、NT-pro BNP的变化。结果治疗组总有效率为90.0%,对照组总有效率为59.1%,2组总有效率的差异有统计学意义(P<0.05)。治疗组治疗后LVEDD为(60.4±6.5)mm,治疗前为(65.7±7.2)mm;对照组治疗后LVEDD为(63.8±7.4)mm,治疗前为(66.1±75.0)mm;2组治疗后差异有统计学意义(P<0.05)。治疗组治疗后LVEF为(46.2±11.9)%,治疗前为(29.1±11.3)%;对照组治疗后为(42.4±13.2)%,治疗前为(29.3±11.0)%;2组治疗后差异有统计学意义(P<0.05)。治疗组治疗后NT-pro BNP为(302.0±36.2)pg/m L,治疗前为(1895.0±20.6)pg/m L;对照组治疗后为(612.0±45.2)pg/m L,治疗前为(1886.0±23.4)pg/m L;2组治疗后差异有统计学意义(P<0.05)。结论在对照组的基础上联合应用富马酸比索洛尔和心舒1号可以降低LVEDD,显著提升LVEF,使NT-pro BNP明显下降,有益于慢性心力衰竭的治疗。Objective Evaluation of the efficacy of the combination of bisoprolol fumarate and diastolic heart failure treatment on the 1 st. Methods 88 chronic heart failure patients were randomLy divided into treatment group and control group （n=44）; the control group conventional therapy： a low-salt diet, adequate rest, proper aerobic exercise, diuretics, digoxin, nitrates, the treatment group in the above treatment based on the use ofbisoprolol fumarate and diastolic on the 1 st. The overall effect of the two groups. Before treatment and after 4 months were done echocardiography were compared LVEDD, changes in LVEF, NT-proBNP in. Results The total effective rate was 90.0% in the control group, the total effective rate was 59.1%, the total difference between the two groups was statistically significant efficiency （P〈0.05）. After treatment LVEDD was （60.4 4, 6.5）mm, was （65.7 ±7.2）mm before treatment; control group after treatment LVEDD was （63.8±7.4）mm, was （66.1±75.0）mm before treatment, significant difference was statistically significant （P〈0.05）. After treatment, LVEF was （46.2±11.9）%, before treatment is （29.1±11.3）%; control group after treatment was （42.4±13.2）%, before treatment was （29.3±11.0）%, a significant difference was statistically significant （P〈0.05）. Treatment group after treatment NT-proBNP was （302.0±36.2）pg / mL, before treatment was （1895.0 4. 20.6）pg/mL; the control group was （612.0±45.2）pg/mL, before treatment was （1886±23.4）pg/mL, significantly different, there was statistically significant （P〈0.05）. Conclusion In the control group on the basis of the combination of bisoprolol fumarate and diastolic reduces the 1 st LVEDD, significantly improved LVEF, so that NT-proBNP decreased, beneficial treatment of chronic heart failure.

关 键 词：心力衰竭 富马酸比索洛尔 心舒1号 Β1受体阻滞剂 

分 类 号：R541.6[医药卫生—心血管疾病]